Key Insights

Highlights

Treatment Research

2 treatments under study, led by Perioperative Treatment With Albuminbound Paclitaxel Oxaliplatin Tegafurgimeracil And Oteracil Porassium Capsules And Sintilimab

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Recruiting2

Clinical Trials (2)

Research Network

Common Treatments

  • Perioperative Treatment With Albuminbound Paclitaxel Oxaliplatin Tegafurgimeracil And Oteracil Porassium Capsules And Sintilimab1
  • Perioperative Treatment1

Active Sponsors

  • Peking University Cancer Hospital & Institute2

Top Investigators

Activity Timeline